| Literature DB >> 35956404 |
Virginia Boccardi1, Francesca Mancinetti1, Marta Baroni1, Roberta Cecchetti1, Patrizia Bastiani1, Carmelinda Ruggiero1, Patrizia Mecocci1,2.
Abstract
BACKGROUND: Inflammation, along with aging processes, contributes to the development of insulin resistance (IR), but the roles of different inflammatory and other cytokines in this process remain unclear. Thus, we aimed to analyze the association between several plasma cytokines with IR as evaluated by the metabolic score for insulin resistance, METS-IR.Entities:
Keywords: aging; gender; inflammation; insulin; metabolism; obesity
Mesh:
Substances:
Year: 2022 PMID: 35956404 PMCID: PMC9370138 DOI: 10.3390/nu14153228
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Demographic and clinical characteristics of the total population sample (n = 132), stratified by gender.
| Total Sample | Men | Women |
| |
|---|---|---|---|---|
| Age, year | 78.5 ± 6.5 | 86.12 ± 6.45 | 78.1 ± 6.9 | 0.436 |
| Weight | 67.2 ± 12.3 | 73.7 ± 10.5 | 63.3 ± 11.7 | <0.0001 |
| Height | 159.1 ± 9.1 | 167.2 ± 6.8 | 154.2 ± 167.2 | <0.0001 |
| BMI | 26.4 ± 4.2 | 26.3 ± 3.4 | 26.5 ± 4.6 | 0.746 |
| Glucose (mg/dL) | 102.1 ± 28.5 | 103.5 ± 26.6 | 101.2 ± 29.7 | 0.661 |
| Cholesterol total (mg/dL) | 205.0 ± 42.7 | 193.7 ± 47.4 | 212.0 ± 38.7 | 0.017 |
| LDL-Cholesterol (mg/dL) | 122.4 ± 36.9 | 112.8 ± 39.1 | 127.9 ± 34.8 | 0.037 |
| HDL-Cholesterol (mg/dL) | 57.7 ± 14.7 | 53.0 ± 14.3 | 60.5 ± 14.3 | 0.004 |
| Triglicerides (mg/dL) | 129.4 ± 57.3 | 131.4 ± 68.4 | 128.1 ± 49.7 | 0.749 |
| CRP (mg/L) | 0.47 ± 0.68 | 0.52 ± 0.92 | 0.45 ± 0.54 | 0.628 |
| Clearance creatinine (BIS1) | 67.5 ± 21.6 | 66.8 ± 21.6 | 67.9 ± 21.7 | 0.796 |
| METS-IR | 38.4 ± 8.0 | 39.2 ± 8.2 | 37.9 ± 7.8 | 0.345 |
BMI: Body mass index; CRP: C-reactive protein; METS-IR: metabolic score for insulin resistance.
Linear regression analyses exploring the association of IL15 with METS-IR, controlling for multiple confounding factors in the studied population (n = 132).
| B | CI 95% |
| |
|---|---|---|---|
|
| |||
| Age | −0.168 | −0.375; 0.040 | 0.112 |
| Gender | 1.319 | −1.487; 4.125 | 0.354 |
| IL-15 | −0.508 | −0.990; 0.025 | 0.039 |
|
| |||
| Age | 0.110 | 0.019; 0.201 | 0.018 |
| Gender | 1.734 | 0.542; 2.926 | 0.005 |
| IL-15 | −0.090 | −0.121; -0.301 | 0.400 |
| BMI | 1.755 | 1.611; 1.899 | <0.0001 |
BMI: Body mass index. Gender indicated as: women = 0, men = 1. Model 1, R2 0.057; Model 2, R2 0.831.
Plasmatic levels of cytokines in the studied population, stratified by gender.
| Men | Women |
| |
|---|---|---|---|
| EGF | 40.7 ± 54.0 | 48.6 ± 40.8 | 0.633 |
| Eotaxin | 142.8 ± 70.1 | 147.7 ± 93.6 | 0.749 |
| G-CSF | 35.1 ± 17.6 | 45.5 ± 45.2 | 0.092 |
| GM-CSF | 6.5 ± 2.6 | 7.8 ± 5.1 | 0.107 |
| INF-A2 | 50.6 ± 14.1 | 54.7 ± 21.5 | 0.239 |
| INF- gamma | 6.7 ± 2.4 | 7.6 ± 4.1 | 0.160 |
| IL-10 | 1.7 ± 1.8 | 2.5 ± 5.7 | 0.298 |
| IL-12 p 40 | 9.0 ± 19.5 | 20.8 ± 42.0 | 0.066 |
| IL-12 p 70 | 6.9 ± 3.5 | 7.3 ± 8.0 | 0.772 |
| IL-13 | 14.2 ± 5.9 | 11.2 ± 5.5 | 0.770 |
| IL-15 | 2.2 ± 1.26 | 2.6 ± 3.4 | 0.442 |
| IL-17 | 8.3 ± 2.3 | 8.1 ± 3.7 | 0.730 |
| IL-1 RA | 22.6 ± 12.0 | 31.2 ± 15.2 | 0.734 |
| IL-1 a | 53.4 ±11.8 | 54.8 ± 27.4 | 0.750 |
| IL-1 b | 2.7 ± 0.8 | 3.1 ± 1.8 | 0.195 |
| IL-2 | 0.9 ± 1.0 | 1.5 ± 3.1 | 0.190 |
| IL-3 | 0.58 ± 0.11 | 0.53 ± 0.12 | 0.039 |
| IL-4 | 10.6 ± 7.11 | 9.6 ± 10.2 | 0.568 |
| IL-5 | 1.8 ± 7.3 | 2.2 ± 10.6 | 0.810 |
| IL-6 | 1.4 ± 1.1 | 2.4 ± 3.1 | 0.024 |
| IL-7 | 1.4 ± 1.9 | 2.5 ± 3.3 | 0.032 |
| IL-8 | 4.7 ± 8.2 | 6.7 ± 10.8 | 0.251 |
| IP-10 | 722.8 ± 425.5 | 821.2 ± 454.1 | 0.221 |
| MCP-1 | 391.0 ± 154.4 | 435.3 ± 271.8 | 0.295 |
| MIP-1 a | 3.6 ± 6.8 | 5.2 ± 9.2 | 0.289 |
| MIP-1 b | 22.6 ± 17.2 | 24.8 ± 23.2 | 0.559 |
| TNF-a | 18.0 ± 10.3 | 21.1 ± 16.1 | 0.237 |
| TNF-b | 11.5 ± 5.2 | 15.9 ± 7.0 | 0.705 |
| VEGF | 155.0 ± 54.3 | 197.5 ± 30.8 | 0.337 |
| RANTES | 37008 ± 38721 | 38278 ± 33646 | 0.843 |
Cytokines are expressed in pg/mL.
Linear regression analyses exploring the association of EGF (Epidermal Growth Factor) with METS-IR, controlling for multiple confounding factors in women (n = 82).
| B | CI 95% |
| |
|---|---|---|---|
|
| |||
| Age | −0.192 | −0.415; 0.030 | 0.089 |
| TC | 0.012 | −0.030; 0.054 | 0.561 |
| HDL-C | −0.235 | −0.345; −0.126 | <0.0001 |
| EGF | 0.016 | 0.001; 0.030 | 0.037 |
|
| |||
| Age | 0.091 | 0.042; 0.140 | <0.0001 |
| TC | 0.000 | −0.009; 0.009 | 0.956 |
| HDL-C | −0.165 | −0.189; −0.142 | <0.0001 |
| EGF | −0.001 | −0.004; 0.002 | 0.571 |
| BMI | 1.532 | 1.457; 1.607 | <0.0001 |
TC: total cholesterol; HDL-C: HDL cholesterol; BMI: body mass index. Model 1, R2 0.257; Model 2 R2 0.967.
Linear regression analyses exploring the association of Eotaxin with METS-IR, controlling for multiple confounding factors in women (n = 82).
| B | CI 95% |
| |
|---|---|---|---|
|
| |||
| Age | −0.184 | −0.396; 0.027 | 0.087 |
| TC | 0.018 | −0.022; 0.058 | 0.374 |
| HDL-C | −0.273 | −0.378; −0.168 | <0.0001 |
| Eotaxin | 0.029 | 0.130; 0.450 | 0.001 |
|
| |||
| Age | 0.092 | 0.040; 0.141 | <0.0001 |
| TC | 0.000 | −0.009; 0.009 | 0.956 |
| HDL-C | −0.163 | −0.187; −0.139 | <0.0001 |
| Eotaxin | −0.001 | −0.005; −0.003 | 0.522 |
| BMI | 1.537 | 1.458; 1.616 | <0.0001 |
TC: total Cholesterol; HDL-C: HDL Cholesterol; BMI: body mass index. Model 1, R2 0.328; Model 2, R2 0.967.
Linear regression analyses exploring the association of MCP-1 (Monocyte Chemoattractant Protein-1) with METS-IR, controlling for multiple confounding factors in women (n = 82).
| B | CI 95% |
| |
|---|---|---|---|
|
| |||
| Age | −0.164 | −0.384; 0.055 | 0.139 |
| TC | 0.011 | −0.029; 0.052 | 0.578 |
| HDL-C | −0.256 | −0.364; −0.149 | <0.0001 |
| MCP-1 | 0.008 | 0.002; 0.111 | 0.007 |
|
| |||
| Age | 0.090 | 0.042; 0.139 | <0.0001 |
| TC | 0.000 | −0.008; 0.009 | 0.940 |
| HDL-C | −0.164 | −0.188; −0.141 | <0.0001 |
| MCP-1 | 0.000 | −0.002; 0.001 | 0.522 |
| BMI | 1.535 | 1.458; 1.611 | <0.0001 |
TC: total cholesterol; HDL-C: HDL cholesterol; BMI: body mass index. Model 1, R2 0.285; Model 2 R2 0.967.